Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s ...
Natera reported outstanding Q1 2023 financial results, with revenues soaring to $241.8 million, marking a 24.5% increase from the same period in 2022. The company's product revenues witnessed a ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...
SAN CARLOS, Calif. & DALLAS--(BUSINESS WIRE)--Natera, a leading innovator in prenatal genetic testing, today announced the initiation of a distribution partnership with ProPath, a wholly ...
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ:ILMN) and Natera, Inc. today announced they have entered into a three-year agreement whereby Illumina will supply Natera with the HiSeq® 2500 ...
When Mara Varona was pregnant she decided to take a common prenatal blood test to screen for genetic conditions. It was part of a proactive approach she and her husband took to pregnancy. "We're just ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE: NVTA), a leading medical ...
Since 2020, Desmarais LLP partner Kerri-Ann Limbeek has represented prenatal testing client Ravgen in eight patent cases in district court and at the Patent Trial and Appeal Board. This week, in her ...
Investor's Business Daily on MSN
Medical stock hovers near buy point after 46% gain
The company has a platform for cell-free DNA testing for prenatal tests, cancer diagnostics and rejection assessments for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback